RE:RE:RE:RE:RE:Anakinra Attenuates Glioblastoma Aggressiveness"Yes, good stuff, poof. So why did Bioasis drop all discussion of the most valuable uses for xB3? Do you have a theory for that?"
The presentation openly claimed xB3 outperforms competing technologies and listed the criteria. That is a huge statement. Multi billion dollar market cap Denali was explicitly mentioned with its stock symbol, etc. Biodexa highlighted multiple xB3 deals with >US$200 million in potential payments as validation for xB3 in the Midatech news release as a reason for the deal. The potential and validation of xB3 to date has been openly highlighted. You act as though xB3 is being hidden. Midatech explicitly mentioned the xB3 deals; including J&J the largest healthcare company in the world. The broad applicability of xB3 from enzymes, to monoclonal antibodies, to oligos was mentioned. Rathjen explicitly said just because of the code of silence with partners doesn't mean there is a lot going on. Biodexa is a path to controlling the company's own destiny with a solid financial footing, pipeline of catalysts, and the scale and capital market profile to get it done. NASDAQ has arrived.
"Bioasis is also developing xB3 delivery technology for various rare and orphan neurodegenerative diseases and has entered into licensing and co-development agreements with potential payments, should various performance conditions and milestones be met, totalling in excess of US$200 million plus royalties on net sales with Chiesi Farmaceutici SpA, Prothena Corporation plc and Neuramedy Co. Ltd. Bioasis also has a research agreement with Janssen Pharmaceutica NV, a Johnson & Johnson subsidiary." Midatech news release
Whereas EGF is poised for clinical trials xB3 appears to still be development stage. Preclinical xB3 Hunter data will be released in Q2 and may not even be known yet. Is there something new? Get the preclinical data and a proof of principle in human clinical trials for xB3 and Biodexa will be able to support a pipeline of xB3 assets. Getting xB3 on a solid financial footing for once and out of a state of threat of perpetual bankruptcy is key and doing it at a time of general carnage in the biotech market with much of the industry trading below cash in recent months doesn't come without a price; especially for a comany in debt to begin that had to use additional debt to pay for Ladenberg Thalmann to help rescue it.